SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 19, 2018--
Vaxart, Inc. (NASDAQ:VXRT), a clinical-stage biotechnology company
developing oral recombinant vaccines that are administered by tablet
rather than by injection, today announced the appointment of Brant Biehn
as Senior Vice President, Commercial Operations. Mr. Biehn brings over
27 years of commercial planning, market development and sales experience
in the pharmaceutical industry.
“We are delighted to welcome Brant to Vaxart. He is a seasoned leader
with a wealth of sales and marketing experience within the
pharmaceutical and vaccine industry,” said Wouter Latour, chief
executive office of Vaxart. “That combination will be invaluable as we
advance our therapeutic and prophylactic product candidates through the
clinic toward commercialization. We look forward to his contributions as
we further establish Vaxart as a leader in the development of antivirals
and vaccines.”
Prior to joining Vaxart, Mr. Biehn served as a consultant, where his
role included business development, investor relations, and general
management for a variety of pharmaceutical and medical device companies.
Earlier, he served as chief commercial officer at Dynavax Technologies
Corporation, where he helped raised significant capital and was
responsible for the development and execution of Dynavax’s commercial
strategy, including global sales, marketing and supply chain management,
leading a team of 70 professionals preparing to launch Heplisav®.
Before Dynavax, Mr. Biehn held sales and marketing positions of
increasing seniority at Merck, culminating in the position of Global
Brand Leader with global responsibility for the manufacturing,
commercial, clinical and regulatory acitivites for vaccines such as
ZOSTAVAX®, PNEUMOVAX®, RECOMBIVAX HB®
and VAQTA®.
Mr. Biehn holds a Bachelor of Science in Computer Science from the
Memorial University of Newfoundland.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing
oral recombinant protein vaccines based on its proprietary oral vaccine
platform. Vaxart’s vaccines are designed to generate broad and durable
immune responses that protect against a wide range of infectious
diseases and may be useful for the treatment of chronic viral infections
and cancer. Vaxart’s vaccines are administered using a convenient room
temperature-stable tablet, rather than by injection. Vaxart believes
that tablet vaccines are easier to distribute and administer than
injectable vaccines, and have the potential to significantly increase
vaccination rates. Vaxart’s development programs include oral tablet
vaccines that are designed to protect against norovirus, seasonal
influenza and respiratory syncytial virus (RSV), as well as a
therapeutic vaccine for human papillomavirus (HPV). Vaxart is also
developing several small-molecule antiviral drug candidates, including
teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV
types 6 and 11. For more information, please visit www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve
substantial risks and uncertainties. All statements, other than
statements of historical facts, included in this press release regarding
our strategy, prospects, plans and objectives, results from preclinical
and clinical trials, commercialization agreements and licenses, beliefs
and expectations of management are forward-looking statements. These
forward-looking statements may be accompanied by such words as
“believe,” “could,” “potential”, “will” and other words and terms of
similar meaning. Examples of such statements include, but are not
limited to, statements relating to the Vaxart’s ability to develop and
commercialize its product candidates, clinical results and trial data,
Vaxart’s ability to obtain and maintain regulatory approval of its
product candidates and Vaxart’s reliance on third party funding and
grants. Vaxart may not actually achieve the plans, carry out the
intentions or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance on
these forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that Vaxart makes, that Vaxart’s product
candidates may not be approved by the FDA or non-U.S. regulatory
authorities; that, even if approved by the FDA or non-U.S. regulatory
authorities, Vaxart’s product candidates may not achieve broad market
acceptance; and the risks described in the “Risk Factors” sections of
the Registration Statement on Form S-4 (file no. 333-222009) and of
Vaxart’s periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as required
by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180419005430/en/
Source: Vaxart, Inc.
Stern Investor Relations
Carl Mauch, 212-362-1200
vaxart@sternir.com